Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 23, 2020, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2020.

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results

Pasadena. CA | Posted on November 3rd, 2020

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 8492751.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 8492751.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Quantum quirk yields giant magnetic effect, where none should exist: Study opens window into the landscape of extreme topological matter March 1st, 2021

How photoblueing disturbs microscopy February 26th, 2021

Changing the silkworm's diet to spin stronger silk February 26th, 2021

From microsaws to nanodrills: laser pulses act as subtle machining tools: Industrial-grade materials processing on the sub-micron scale is enabled by spatially structured ultrashort laser pulses February 26th, 2021

Possible Futures

Quantum quirk yields giant magnetic effect, where none should exist: Study opens window into the landscape of extreme topological matter March 1st, 2021

Bioinformatics tool accurately tracks synthetic: DNA Computer scientists show benefits of bioinformatics with PlasmidHawk February 26th, 2021

How photoblueing disturbs microscopy February 26th, 2021

Changing the silkworm's diet to spin stronger silk February 26th, 2021

Investments/IPO's/Splits

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Grapheal raises EUR1.9 million to advance development of embedded biosensing technology and application in digital COVID testing and wound monitoring: Includes seed financing from Novalis Biotech and private investors, support from Bpifrance as well as non-dilutive grants February 10th, 2021

180 Degree Capital Corp. Issues Open Letter to the Board and Shareholders of Enzo Biochem, Inc. February 4th, 2021

Nanomedicine

How photoblueing disturbs microscopy February 26th, 2021

Changing the silkworm's diet to spin stronger silk February 26th, 2021

Nanoparticles help untangle Alzheimer's disease amyloid beta plaques: New research shows that the protein that causes Alzheimer's disease's hallmark brain plaques clings to certain bowl-shaped nanoparticles, allowing researchers to better understand the disease and potentially pr February 26th, 2021

Fantastic voyage: Nanobodies could help CRISPR turn genes on and off: Stanford researchers attached biological nanobodies to the CRISPR DNA editing tool in an experimental combo designed to extend the usefulness of two promising molecular tools February 25th, 2021

Announcements

Quantum quirk yields giant magnetic effect, where none should exist: Study opens window into the landscape of extreme topological matter March 1st, 2021

From microsaws to nanodrills: laser pulses act as subtle machining tools: Industrial-grade materials processing on the sub-micron scale is enabled by spatially structured ultrashort laser pulses February 26th, 2021

Nanoparticles help untangle Alzheimer's disease amyloid beta plaques: New research shows that the protein that causes Alzheimer's disease's hallmark brain plaques clings to certain bowl-shaped nanoparticles, allowing researchers to better understand the disease and potentially pr February 26th, 2021

Researchers improve efficiency of next-generation solar cell material: Reducing internal losses could pave the way to low-cost perovskite-based photovoltaics that match silicon cells’ output February 26th, 2021

Financial Reports

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results January 20th, 2021

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results November 23rd, 2020

Events/Classes

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results January 20th, 2021

SEMICON Japan 2020 Virtual Set to Open with Sustainable Industry Growth, Smart Technology in the Spotlight December 8th, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences December 2nd, 2020

Nanobiotechnology

Changing the silkworm's diet to spin stronger silk February 26th, 2021

Nanoparticles help untangle Alzheimer's disease amyloid beta plaques: New research shows that the protein that causes Alzheimer's disease's hallmark brain plaques clings to certain bowl-shaped nanoparticles, allowing researchers to better understand the disease and potentially pr February 26th, 2021

Fantastic voyage: Nanobodies could help CRISPR turn genes on and off: Stanford researchers attached biological nanobodies to the CRISPR DNA editing tool in an experimental combo designed to extend the usefulness of two promising molecular tools February 25th, 2021

Dynamics of nanoparticles using a new isolated lymphatic vessel lumen perfusion system February 19th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project